Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$0.48 - $0.85 $65 - $116
137 New
137 $0
Q2 2023

Aug 14, 2023

SELL
$0.98 - $1.11 $16 - $18
-17 Reduced 9.88%
155 $0
Q1 2023

May 15, 2023

BUY
$0.98 - $1.06 $5 - $6
6 Added 3.61%
172 $0
Q4 2022

Feb 14, 2023

SELL
$0.96 - $28.0 $60 - $1,764
-63 Reduced 27.51%
166 $0
Q3 2022

Nov 14, 2022

BUY
$1.06 - $27.75 $46 - $1,221
44 Added 23.78%
229 $0
Q2 2022

Aug 15, 2022

SELL
$1.07 - $1.55 $1,212 - $1,756
-1,133 Reduced 85.96%
185 $0
Q1 2022

May 16, 2022

SELL
$1.21 - $2.24 $2,084 - $3,859
-1,723 Reduced 56.66%
1,318 $2,000
Q4 2021

Feb 14, 2022

BUY
$2.02 - $3.36 $3,801 - $6,323
1,882 Added 162.38%
3,041 $7,000
Q3 2021

Nov 15, 2021

BUY
$2.96 - $36.67 $1,145 - $14,191
387 Added 50.13%
1,159 $4,000
Q2 2021

Aug 16, 2021

BUY
$31.5 - $42.5 $24,318 - $32,810
772 New
772 $26,000

Others Institutions Holding FBRX

# of Institutions
1
Shares Held
175K
Call Options Held
0
Put Options Held
0

About Forte Biosciences, Inc.


  • Ticker FBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,340,300
  • Market Cap $371M
  • Description
  • Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
More about FBRX
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.